Financial Lp Hrt Sells 18,531 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 18,531 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $3.52, for a total value of $65,229.12. Following the completion of the sale, the insider directly owned 52,274 shares of the company’s stock, valued at approximately $184,004.48. The trade was a 26.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.33, for a total value of $35,231.40.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Trading Down 8.1%

Shares of NASDAQ:SHPH traded down $0.29 on Thursday, hitting $3.28. The company had a trading volume of 125,987 shares, compared to its average volume of 555,046. Shuttle Pharmaceuticals Holdings, Inc. has a 1-year low of $2.90 and a 1-year high of $55.90. The stock has a market cap of $2.10 million, a price-to-earnings ratio of -0.07 and a beta of 0.29. The stock has a 50 day moving average price of $5.30 and a 200 day moving average price of $10.27.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SHPH. Connective Capital Management LLC bought a new position in Shuttle Pharmaceuticals during the third quarter worth about $357,000. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter worth about $26,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at about $37,000. Finally, Ikarian Capital LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at about $124,000. 4.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on SHPH. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .